Wegovy vs Ozempic: Same Molecule, Different Label

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide comes from the PlexusDx Education Hub, our library of plain-language explainers on GLP-1 therapy, weight management, and the genetic factors that quietly shape metabolic outcomes. Browse all Peptides & GLP-1 education

Consider this an independent editorial breakdown. PlexusDx has no financial relationship with Novo Nordisk or any manufacturer named below.

Unlike most brand comparisons, Wegovy versus Ozempic is not a contest between two drugs. It is one drug — semaglutide — packaged under two names for two purposes. Understanding that single fact reframes the entire question, so we start there and build outward to dosing, indication, evidence, cost, and the genetics that precede any of it.

One active ingredient, two names

Both Ozempic and Wegovy are semaglutide from Novo Nordisk, a GLP-1 receptor agonist that slows gastric emptying, smooths post-meal glucose, and strengthens satiety signaling. The difference is not the molecule; it is the labeled dose and the approved use. For context, tirzepatide is a GIP/GLP-1 dual agonist, liraglutide and dulaglutide are GLP-1-selective, and retatrutide is an investigational triple agonist not FDA-approved as of April 2026.

The dose ceiling that separates them

The practical line between the two brands is the top of the dosing ladder. Wegovy titrates to a higher maintenance dose (2.4 mg) built around chronic weight management, while Ozempic's dosing sits within its diabetes labeling. Because it is the same molecule, escalation is gradual in both to limit gastrointestinal side effects — the strategy is shared even when the ceiling is not.

Diabetes label versus weight label

Approvals track indication, not chemistry. Ozempic (semaglutide) was approved for type 2 diabetes in 2017; Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021; Rybelsus (oral semaglutide) for type 2 diabetes in 2019. For comparison across the class: Mounjaro (2022) and Zepbound (2023, plus 2024 sleep apnea) are tirzepatide; Trulicity (2014) is dulaglutide; Victoza (2010) is liraglutide. Retatrutide is not approved.

Evidence behind each brand

Semaglutide's record runs through STEP (weight management) and SUSTAIN and SELECT (diabetes and cardiovascular outcomes). Head-to-head data within the class is trial-specific: SUSTAIN 7 compared semaglutide 1 mg with dulaglutide 1.5 mg, and SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes. Because Wegovy and Ozempic are the same compound, the evidence question is less "which molecule" and more "which dose and indication."

Side effects when the molecule is identical

With one shared ingredient, the safety profile is essentially the same. Both carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies and are contraindicated in patients with a history of medullary thyroid carcinoma or MEN 2. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are most prominent during escalation. Rare serious events include pancreatitis, gallbladder disease, and dehydration-related kidney injury.

List price and coverage reality

As of April 2026, U.S. list prices across the FDA-approved brands run roughly $815 to $1,620 per month per manufacturer-published pricing. Actual spending depends on insurance, the indication on the script, savings-card eligibility, and compounded-alternative availability through licensed pathways. Coverage often diverges sharply between a diabetes label and a weight-management label even for the identical molecule.

Genetics upstream of semaglutide

Whether the label reads Ozempic or Wegovy, the receptor is the same and so is the genetic backdrop. GLP1R encodes the target itself; FTO influences appetite and adiposity set-point; MC4R governs energy balance; and TCF7L2 connects to glucose regulation and GLP-1 secretion. These pathway-level variants do not forecast your response to semaglutide, but they outline the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2 — pairing the medication with the upstream context most programs skip.

Related reading on PlexusDx: Ozempic Face, Ozempic Side Effects, and Ozempic Price.

Editorial note: this article is educational. PlexusDx offers only semaglutide and tirzepatide in the GLP-1 category and does not sell, prescribe, or recommend dulaglutide, liraglutide, retatrutide, cagrilintide, or related compounds. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified provider before beginning a protocol.

Start upstream: take the Precision Peptide Genetic Test, or see the Weight Management Protocols.

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

Yes, at the molecular level. Both are semaglutide made by Novo Nordisk. They differ in labeled dose and FDA indication rather than active ingredient: Ozempic is labeled for type 2 diabetes, while Wegovy is labeled for chronic weight management at a higher maintenance dose.

Can Ozempic be used for weight loss instead of Wegovy?

Ozempic's FDA indication is type 2 diabetes, and Wegovy carries the weight-management indication for the same molecule. How a provider approaches an individual case is a clinical decision made with the patient. This article is educational and not a recommendation to use any product off-label.

Is the maximum dose the same for both?

No. Wegovy titrates to a higher maintenance dose (2.4 mg) designed for weight management, whereas Ozempic's dosing sits within its diabetes labeling. Both escalate gradually from a low starting dose to reduce gastrointestinal side effects during the ramp-up period.

Does a genetic test say which semaglutide dose will work?

No. The Precision Peptide Genetic Test does not predict response to Ozempic, Wegovy, or any dose. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline semaglutide-relevant biology — useful context, not a prediction.

Keep learning at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.